Compare EVLV & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVLV | PHAR |
|---|---|---|
| Founded | 2013 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 988.3M | 1.1B |
| IPO Year | N/A | N/A |
| Metric | EVLV | PHAR |
|---|---|---|
| Price | $6.97 | $16.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $9.13 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 2.9M | 21.0K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | $136,501,000.00 | ★ $362,274,000.00 |
| Revenue This Year | $41.14 | $24.80 |
| Revenue Next Year | $14.60 | $6.84 |
| P/E Ratio | ★ N/A | $3,084.39 |
| Revenue Growth | ★ 43.16 | 26.78 |
| 52 Week Low | $2.64 | $7.50 |
| 52 Week High | $8.91 | $18.12 |
| Indicator | EVLV | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 53.91 |
| Support Level | $6.52 | $15.76 |
| Resistance Level | $6.78 | $18.12 |
| Average True Range (ATR) | 0.24 | 0.80 |
| MACD | 0.13 | -0.02 |
| Stochastic Oscillator | 80.58 | 54.66 |
Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.